Evidence map›Paper›PMID 39489531›Full record

ArticleRMD open2024

Impact of patient characteristics on ASDAS disease activity state cut-offs in axial spondyloarthritis: results from nine European rheumatology registries.

Lykke M Ørnbjerg, Stylianos Georgiadis, Tore K Kvien, Brigitte Michelsen, Simon Rasmussen, Karel Pavelka, Jakub Zavada, Anne Gitte Loft, Gokce Kenar, Dilek Solmaz and 15 more

Abstract read
In one paragraph

Article in RMD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Lykke M ØrnbjergCopenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark lykke.midtboell.oernbjerg@regionh.dk.ORCID 0000-0002-7832-6831
Stylianos GeorgiadisCopenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0003-3485-9457
Tore K KvienCenter for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.ORCID 0000-0002-8441-3093
Brigitte MichelsenCopenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark.
Simon RasmussenCopenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark.
Karel PavelkaInstitute of Rheumatology, Prague, Czech Republic.
Jakub ZavadaInstitute of Rheumatology, Prague, Czech Republic.
Anne Gitte LoftDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Gokce KenarDepartment of Internal Medicine, Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey.
Dilek SolmazIzmir Katip Celebi University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir Ataturk Education and Research Hospital, Izmir, Turkey.ORCID 0000-0002-9035-689X
Bente GlintborgCopenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-8931-8482
Ana RodriguesRheumatology Unit, Hospital dos Lusíadas, Lisbon, Portugal.
Maria Jose SantosReuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal.ORCID 0000-0002-7946-1365
Daniela Di GuiseppeDivision of Clinical Epidemiology, Department of Medicin Solna, Karolinska Institutet, Stockholm, Sweden.
Johan K WallmanDepartment of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden.
Adrian CiureaDepartment of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-7870-7132
Michael J NissenDepartment of Rheumatology, University Hospital of Geneva, Geneva, Switzerland.ORCID 0000-0002-6326-1764
Ziga RotarFaculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.ORCID 0000-0002-9323-9189
Katja Perdan PirkmajerFaculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Dan NordströmDepartments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland.
Anna Mari HokkanenDepartments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland.
Bjorn GudbjornssonCentre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland.ORCID 0000-0003-4631-6505
Olafur PalssonDepartment of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden.
Merete Lund HetlandCopenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0003-4229-6818
Mikkel ØstergaardCopenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo re-evaluate cut-offs for disease activity states according to the Axial Spondyloarthritis Disease Activity Score (ASDAS), and study the impact of sex, age, calendar time, disease and symptom duration on ASDAS and ASDAS cut-offs in a large contemporary cohort.

methodsData from 2939 patients with axial spondyloarthritis (axSpA) starting their first tumour necrosis factor inhibitor in nine European registries were pooled and analysed. Receiver operating characteristic analyses were performed to identify cut-offs against external criteria. Six-month data including patient and physician global assessments, both ≤1 (0-10 integer scale), and Assessment of SpondyloArthritis International Society partial remission were used for separation of inactive disease (ID) from low disease activity (LDA), while patient and physician global ≤3 were applied as external criteria to separate LDA from high disease activity (HDA). Patient and physician global ≥6 were applied to separate HDA from very high disease activity in baseline data.

resultsThe three ASDAS cut-offs identified to separate the four disease activity states in the overall patient population were <1.3, <2.0 and >3.5. Cut-offs for ID and LDA in women were higher (<1.5 and <2.0, respectively) than in men (<1.3 and <1.9), as were cut-offs in patients ≥45 years (<1.5 and <2.2) versus ≤34 years (<1.2 and <1.9) and 35-44 years (<1.3 and <1.8). Cut-offs were independent of calendar time and disease duration.

conclusionsRe-evaluation of ASDAS cut-offs for disease activity states in a large multi-national axSpA cohort resulted in cut-offs similar to those currently endorsed. Differences in cut-offs between sex and age groups for ID and LDA were observed, but the differences were minor.

Indexed as

Axial SpondyloarthritisRegistriesSeverity of Illness IndexAdultAge FactorsEuropeFemaleHumansMaleMiddle AgedRheumatologyROC CurveSex FactorsTumor Necrosis Factor InhibitorsTumor Necrosis Factor InhibitorsAxial SpondyloarthritisDisease ActivityEpidemiology

Identifiers

PMID39489531
PMCPMC11535712

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.